← Eichor
Condition: Post Polycythemia Vera Myelofibrosis Post Pv Mf Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Post Polycythemia Vera Myelofibrosis Post Pv Mf

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myel
Phase N/A · 2 location(s) · MPN Research Foundation · NCT07362225A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms
Phase 1 · 5 location(s) · Prelude Therapeutics · NCT07469891Research Platform Myelofibrosis and Anemia
Phase N/A · 1 location(s) · iOMEDICO AG · NCT06976918Therapeutic RSK1 Targeting in Myelofibrosis
Phase 1 · 1 location(s) · Washington University School of Medicine · NCT07379125Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Resp
Phase 3 · 215 location(s) · Kartos Therapeutics, Inc. · NCT06479135Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal
Phase 1/Phase 2 · 19 location(s) · Telios Pharma, Inc. · NCT05280509A Post-Marketing Surveillance Study to Assess the Safety of Fedratinib in Korean Patients With Myelofibrosis
Phase N/A · 3 location(s) · Bristol-Myers Squibb · NCT06073847A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)
Phase 3 · 21 location(s) · Merck Sharp & Dohme LLC · NCT06351631Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition
Phase 1 · 1 location(s) · Fox Chase Cancer Center · NCT06218628Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis
Phase 2 · 33 location(s) · GlaxoSmithKline · NCT06517875Asian Myeloproliferative Neoplasm (MPN) Registry
Phase N/A · 1 location(s) · The University of Hong Kong · NCT05882773Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis
Phase 1 · 7 location(s) · Novartis Pharmaceuticals · NCT07340138A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF)
Phase 1 · 21 location(s) · Ajax Therapeutics, Inc. · NCT06343805A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
Phase 3 · 30 location(s) · Novartis Pharmaceuticals · NCT07357727Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120)
Phase 2 · 9 location(s) · Icahn School of Medicine at Mount Sinai · NCT05835466Open Label Phase 1/2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibr
Phase 1/Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT06327100
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.